Drugnews

How did Wegovy pill sales compare with Foundayo in Q3 2026?

Novo Nordisk reported on November 4, 2026 that its semaglutide Wegovy pill generated DKK 5.39 billion in Q3 2026 sales, approximately US$813 million, compared with US$184 million for Eli Lilly’s orforglipron Foundayo. Drugnews’s November 10, 2026 analysis describes a 4.4x global revenue ratio; this compares sales across different geographic footprints.

Updated

Oral obesity medicines: reported Q3 2026 revenue
MeasureReported resultBasis
Novo Nordisk / Wegovy pillDKK 5.39 billionGlobal sales; approximately US$813 million
Eli Lilly / FoundayoUS$184 millionSame quarter; geographic scope differs
Drugnews comparison4.4xGlobal revenue ratio, not a clinical comparison

Revenue does not measure head-to-head efficacy or an individual patient’s likely response.

Sources

Read the full analysis

Novo Pill Leads Lilly 4x, Lilly Takes 1/3 of Starts — 2026-11-10